CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 27 enrolled
Drug / intervention
MK-1029 +1 moredrug
Likely dose
MK-1029 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01370317
NCT01370317Phase 1Completed
CompareCT.gov

Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma

Merck Sharp & Dohme LLC·interventional·Posted Jun 9, 2011·Updated Jan 25, 2019

In Brief

A Phase 1 clinical trial evaluating MK-1029 and Placebo for MK-1029 for Asthma. Completed, enrolled 27 participants across 5 sites in 4 countries.

Detailed Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesAustralia, New Zealand, South Africa, United States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 9, 2011
Enrollment StartJun 1, 2011
Primary CompletionDec 27, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.1 years ago

Interventions

MK-1029drug

Five (5) X 100 mg capsules, orally, once daily for 28 days

Placebo for MK-1029drug

Five (5) X 100 mg capsules, orally, once daily for 28 days